Citations

Mayo Clinic

Showing 10 of 108537 citations.

Abstract 13977: Low Operative Mortality Achieved With Surgical Septal Myectomy: Role of Dedicated Hypertrophic Cardiomyopathy Centers in the Management of Dynamic Subaortic Obstruction
Maron, Barry J. , Ommen, Steve R. , Maron, Martin S. , Ralph‐Edwards, Anthony, Balaram, Sandhya K. , Rastegar, Hassan , Rowin, Ethan J. , Smedira, Nicholas G. , Lytle, Bruce W. , Desai, Milind Y. , Lever, Harry M., Dearani, Joseph A. , Schaff, Hartzell V. , Nishimura, Rick A. , Sherrid, Mark V. , Swistel, Daniel G.

Circulation | April 23, 2024 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.13977 Get It

Background: Treatment of progressive heart failure, due to left ventricular (LV) outflow tract obstruction has been a major component of hypertrophic cardiomyopathy (HCM) disease management for 50 years. Septal myectomy has been the primary treatment option to abolish gradients and relieve heart failure symptoms. The role of myectomy in HCM management has depended on effectiveness in relieving heart failure symptoms, but also an acceptable operative risk. Methods: Over the most recent 15-year period, we reviewed 3,700 consecutive isolated myectomy operations performed at major North American HCM institutions. Composite operative mortality (first 30 days) was only 0.4%. Seventeen operative deaths were at ages 24 to 82 (≥70 years), and only 6 occurred after 2010. Notably, 2 of the 4 Mayo Clinic deaths were in patients with prior alcohol septal ablation. Septal myectomy, when performed in experienced HCM centers, was much safer when compared to operative mortality with coronary artery bypass grafting (2.3%); valve replacement (3.5%); mitral valve replacement specifically (5.7%) (STS Database), similar to atrial or ventricular septal defect closure and 15-fold less than myectomy in community hospital or low volume surgical settings. Conclusions: Surgical myectomy performed in dedicated HCM centers with experienced surgeons and staff is one of the safest open-heart procedures currently practiced, with a mortality rate as low as 0.4%. The large mortality discrepancy for myectomy between community hospitals and dedicated HCM centers underscores that this operation should be considered a specialized procedure best performed in high volume HCM institutions.
Abstract 13621: Integrating Metabolomics and Genomics Uncovers Novel Pathways and Genetic Signatures Influencing Hydrochlorothiazide Blood Pressure Response: A Genetic Response Score for Hydrochlorothiazide Use
Shahin, Mohamed H. , Gong, Yan , Beitelshees, Amber L. , Chapman, Arlene B. , Boerwinkle, Eric , Scherer, Steven E. , Rotroff, Daniel M. , Webb, Amy , Langaee, Taimour , McDonough, Caitrin W. , Garrett, Timothy J. , Gums, John G. , Motsinger‐Reif, Alison A. , Chapman, Arlene B. , Turner, Stephen T. , Frye, Reginald F. , Sadée, Wolfgang , Fiehn, Oliver , Cooper‐DeHoff, Rhonda M. , Kaddurah‐Daouk, Rima , Johnson, Julie A.

Circulation | April 23, 2024 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.13621 Get It

Introduction: Hydrochlorothiazide (HCTZ) is among the most commonly prescribed antihypertensives in the US, yet <50% of HCTZ treated patients achieve blood pressure (BP) control. Hypothesis: Integrating metabolomic and genomic profiles of HCTZ treated patients could identify novel pathways/biomarkers for optimizing the use of HCTZ. Methods: Primary analysis included 228 white hypertensives treated with HCTZ from the Pharmacogenomic Evaluation of Antihypertensive Response (PEAR) study. Genotyping was determined via Illumina Omni 1M-Quad Chip and untargeted metabolomics was performed on baseline fasting plasma samples using a GC-TOF MS platform. Pathway analysis was used to integrate metabolites significantly associated with HCTZ BP response (FDR<.05) and genetic signals at p<5x10-5 from HCTZ BP genome-wide analysis. Replication was conducted in another 212 white HCTZ treated patients. Replicated genetic signals were used to create a BP response score by summing their BP lowering alleles. We validated this score by testing it in 196 white HCTZ treated patients in the Genetic Epidemiology of Responses to Antihypertensives (GERA) study. Results: Thirteen metabolites were significantly associated with HCTZ systolic BP (SBP) and diastolic BP (DBP) responses (FDR<.05). Metabolomics-genomics integration revealed significant metabolites along with rs2727563 PRKAG2, rs12604940 DCC, and rs13262930 EPHX2, in the netrin signalling pathway (p=1x10-5), as potential markers significantly influencing HCTZ BP response. We successfully replicated those 3 genetic signals and added their alleles to create a response score which explained 11.3% and 11.9% of the variability to HCTZ SBP and DBP responses, respectively. We found that patients carrying one “response” allele had a significantly worse response than carriers of six alleles (ΔSBP/ΔDBP: -1.5/1.2 vs -16.3/-10.4 mmHg, respectively, SBP score p=1x10-8 and DBP score p=3x10-9). We further validated this response score by testing it in the GERA (DBP score p=0.03, SBP score p=0.07). Conclusion: This study highlights the power of using different omics to identify novel pathways/biomarkers of drug response, and suggests that PRKAG2, DCC and EPHX2 might be important determinants of HCTZ BP response.
Abstract 13556: Elderly Patients Receiving Durable LVAD Support: Insights and Outcomes
Shah, Palak , Desai, Shashank , Rongione, Anthony J., Maltais, Simon, Haglund, Nicholas, Stulak, John M., Salerno, Christoper, Pagani, Francis D. , Dunlay, Shannon M. , Aaronson, Keith D. , Davis, Mary Beth, Cowger, Jennifer

Circulation | April 23, 2024 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.13556 Get It

Introduction: Age ≥ 70 is used to exclude patients from cardiac transplantation. Elderly patients may be offered left ventricular assist device (LVAD) therapy as an alternative. It remains poorly defined how they respond to LVAD support. Hypothesis: Elderly patients have LVAD outcomes that are non-inferior to younger patients. Methods: Data on 1,149 continuous-flow LVAD recipients from May 2004 to May 2015 was pooled from the Mechanical Circulatory Support Research Network (MCSRN). Groups were assigned based on Age ≥ 70 (n = 163) and < 70 (n = 986). Results: Patients age ≥ 70 were more likely to be male (91%), have an ischemic cardiomyopathy (71%), atrial fibrillation (41%), hypertension (66%), diabetes (38%) and prior sternotomy (45%). Older patients also had a lower BMI and higher creatinine, 26.7 ± 0.4 v. 29.9 ± 0.5 and 1.46 ± 0.04 v. 1.35 ± 0.02, p < 0.05. The hazard ratio for mortality was highest in elderly patients in the early post-operative period and stabilized over time with no long-term differences in survival, p = 0.18, Figure 1a. Elderly patients had equivalent rates of device thrombosis and stroke, p = 0.47 and 0.44, Figures 1b-c. Survival free of gastrointestinal bleeding (GIB) at 1-year was 58% in elderly patients compared to 69% in younger patients, Figure 1d, p < 0.01. Multivariate cox regression revealed that age ≥ 70 was not a significant predictor of mortality (HR 0.93, 95% CI 0.69 - 1.25, p = 0.62), but pre-operative creatinine (HR 1.54, 95% CI 1.28 - 1.86, p < 0.01) and bilirubin (HR 1.2, 95% CI 1.03 - 1.4, p = 0.02) were. When age was considered a continuous variable, the HR was 1.2 (95% CI 1.07 - 1.3 per 10y, p < 0.01). Conclusions: Elderly patients, age ≥ 70, have equivalent long-term survival after LVAD implantation with similar rates of device thrombosis and stroke. Rates of GIB were higher in the elderly and this finding warrants caution when choosing anti-coagulation protocols in the elderly. Overall age ≥ 70 does not portend a poorer survival after LVAD implant.
Abstract 13545: ST2 in Heart Failure With Preserved Ejection Fraction
Stevens, Susanna R., Chen, Horng H. , Redfield, Margaret M. , AbouEzzeddine, Omar F. , McKie, Paul M. , Dunlay, Shannon M. , Felker, G. Michael , Borlaug, Barry A. , Tracy, Russell P. , Braunwald, Eugene

Circulation | April 23, 2024 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.13545 Get It

Introduction: In vitro, ST2 is a marker of myocyte stress and inflammation but in vivo, there is no trans-cardiac ST2 concentration step-up to support cardiac ST2 activation in human heart failure (HF) calling into question the source of ST2 in HF. While ST2 is predictive of adverse outcomes in HF, the relationship between ST2 and key pathophysiologic domains in HF with preserved ejection fraction (HFpEF) is not well characterized. Hypothesis: ST2 levels increase in proportion to the severity of left ventricular (LV) remodeling and dysfunction in HFpEF. Methods: At enrollment, patients (n=174) from the RELAX trial testing sildenafil in HFpEF had serum ST2 levels measured and underwent assessment of pathophysiologic domains including congestion, cardiac structure and function, exercise performance (peak oxygen consumption (VO2)) and biomarkers of neurohumoral activation (NT-proBNP, aldosterone, endothelin-1), renal dysfunction (cystatin-C), fibrosis (pro-collagen III N-terminal peptide [NTP], C-telopeptide for type I collagen [CITP]), inflammation (high-sensitivity CRP [hsCRP]) and myocardial necrosis (high-sensitivity troponin-I [hsTnI]). Analysis adjusted for sex, a covariate associated with ST2 levels in normal persons. Results: See table. ST2 was associated with greater congestion, worse right ventricular (RV) pressure overload and dysfunction, lower peak VO2 and biomarkers of neurohumoral activation, renal dysfunction, fibrosis and myocardial necrosis and tended to be associated with systemic inflammation (hsCRP). ST2 was not associated with LV structure or LV systolic or diastolic function. Conclusions: In HFpEF, ST2 was associated with measures of right sided congestion, RV overload and dysfunction, exercise intolerance and other systemic markers of more advanced HF but not with LV structure or LV systolic or diastolic function. These data suggest that mechanisms distinct from LV stress stimulate ST2 activation in HFpEF.
Abstract 12921: Role of Transesophageal Echocardiogram in Affecting Treatment in Older Adults Undergoing Evaluation for Transient Ischemic Attack or Stroke
Woerkom, Ryan C. Van , Davis, Megan L., LaBanc, Austin J., Coakley, Maria , Lester, Stephen J, Temkit, M’hamed, Wilansky, Susan , Demaerschalk, Bart M.

Circulation | April 23, 2024 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.12921 Get It

Background: As the United States medical system transitions to value-based reimbursement, interested parties will increase scrutiny in testing that may not alter management or outcomes. We investigated whether transesophageal echocardiography (TEE) provokes treatment alteration across age strata in hospitalized patients undergoing a TIA/stroke work-up. Methods: Consecutive patients admitted to the Mayo Clinic Arizona healthcare system between 1/1/2010 and 2/9/2015 were evaluated. A total of 832 patients were identified of which 314 were excluded primarily due to the fact that the TEE was performed as an outpatient. Therefore, 518 subjects (mean age = 68.2 +/- 14.1 y, 42.5% female) were included. A change in treatment was defined a priori as: anticoagulation (AC) initiated for atrial fibrillation found on TEE only (i.e. not identified on telemetry), complex proximal aortic arch plaque, left atrial or left atrial appendage thrombus, intracardiac mass, intracardiac shunt (atrial septal defect (ASD)/ patent foramen ovale (PFO)) ; PFO closure; cardiac mass removal; valve replacement for endocarditis; antibiotics for endocarditis. Results: See Tables A & B Conclusion: TEE in the evaluation of hospitalized patients with TIA/stroke resulted in a change in treatment in approximately 7% of patients regardless of age. Many of the decisions to change treatment were judgment-based and therefore adoption of the routine use of TEE in all patients with TIA/stroke is dependent on institutional practice standards.
Abstract 12508: Tuning the Heart Rate Recovery For Age
Sydó, Tibor, Carta, Karina Auristela Gonzalez, Murphy, Joseph G. , Allison, Thomas G. , Sydó, Nóra , Merkely, Béla

Circulation | April 23, 2024 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.12508 Get It

Introduction: Exercise parameters such as peak heart rate (HR) are generally adjusted for age, whereas HR recovery is generally given as an absolute value: < 13 bpm at 1 minute post-peak exercise being abnormal. Hypothesis: We analyzed a large cohort of patients to determine the impact of age on HR recovery (HRRec) and if the prognostic performance of HRRec is improved by adjustment for age. Methods: Non-imaging exercise tests performed on patients aged 30-79 years from 1993 to 2010 were included. Patients with known cardiovascular diseases were excluded. Patients were assigned to 5 groups according to age: 30-39, 40-49, 50-59, 60-69, and 70-79. Mortality was reported according to HRRec during the first minute of active recovery using Cox regression analysis. Mortality was determined from Minnesota and National Death Indices. Results: 22,643 patients (64 % male) were included. The median HRRec in the age groups with IQR were as follows: 30-39: 20 [15-26]; 40-49: 19 [14-25]; 50-59: 18 [13-23]; 60-69: 15 [10-20]; and 70-79: 11 [6-16]. There were 1566 deaths (6.9%) over a mean follow-up of 11.8 ± 5.0 years. HRRec of 13 would fall at the 17 th percentile for patients 30-39 years old, but this increased to the 20 th , 27 th , 40 th , and 60 th percentiles with increasing age group. The mortality in age groups according to HRRec is shown in the Figure. For age groups 30-39 and 40-49, the hazard ratio for mortality at a HRRec of 11-12 bpm (i.e. just below the standard of 13) versus patients with a HRRec of ≥ 20 bpm was > 2.0. For age 50-59 and 60-69, however, a HRRec of < 11 bpm is necessary to obtain a doubling of risk, and for age 70-79 a HRRec of < 9 bpm is necessary. Conclusions: HRRec decreases significantly with age. The performance of abnormal HRRec defined as < 13 bpm is inconsistent across age groups. To standardize the ability of HRRec to identify at least a 2.0-fold increased risk, lowering the cup-point to < 11 bpm for ages 50-59 and 60-69 and < 9 bpm for age 70-79 is required.
Abstract 12496: A New Arrhythmic Threat to America. Chikungunya Myocarditis
Mendoza, Iván , Morr, Igor, Torres, Jaime R. , Gonzalez, Karina, Meza, Yolimar, Villalobos, Iris, Marques, Juan, Misticchio, Francesca, Vasquez, Rosalin, Morr, Carlos, Morr, Claudia

Circulation | April 23, 2024 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.12496 Get It

Background: The mosquito-borne Chikungunya virus infection is one of the most important emerging virus diseases globally. Local transmission has been found in the United States. There are very few published reports concerning the cardiac complications in general and less of arrhythmias in particular. Chikungunya can be fatal: there have been sudden deaths reports . Objective: To investigate arrhythmic complications of Chikungunya myocarditis. Methods: Prospective multicenter observational study of 280 patients with a Chikunguya infection from a Venezuelan Outbreak. Clinical evaluation, ECG, laboratory including virological evaluation and cardiac biomarkers, Echocardiogram, Holter and cardiac MRI procedures were carried out. Results: Of the 280 patients examined, 113 patients were male, with a mean age of 59 ± 9; 270 patients presented with fever and polyarthralgia and 85 developed palpitations. Arrhythmias occured in 45% of cases; they included bradyarrhythmias (33%), atrial and ventricular ectopic beats and tachyarrhythmias in which atrial fibrillation was observed in 19 cases. There were also ectopic atrial tachycardia and non sustained ventricular tachycardia, conduction disturbances and 3 cases of sudden death. Conclusion: Physicians should know that almost half of the Chikungunya patients will develop arrhythmias and manifest or silent myocarditis. In the proper epidemiological context, the triad of fever, polyarthralgia and new arrhythmia including bradiarrhythmias suggest Chikungunya Myocarditis.
Abstract 12075: Telecommunicator CPR Intervention Improves Recognition of Cardiac Arrest and Time to First Chest Compression
Sutter, John, Langlais, Blake, Panczyk, Micah , Vadeboncoeur, Tyler F. , Bobrow, Bentley J., Dameff, Christian , Tully, Jeffrey Logan , Chikani, Vatsal , Spaite, Daniel W.

Circulation | April 23, 2024 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.12075 Get It

Background: Bystander cardiopulmonary resuscitation (BCPR) significantly improves survival from out-of-hospital cardiac arrest (OHCA). Telecommunicator CPR (TCPR) has been shown to increase BCPR rates, yet TCPR performance varies widely. We assess whether a bundled TCPR protocol, training, and continuous quality improvement (CQI) intervention improves TCPR performance. Methods: The intervention was implemented at a regional 9-1-1 dispatch center and had three main components: (1) the installation of the AHA-recommended 2-question TCPR protocol, (2) training to enhance telecommunicator OHCA recognition and (3) CQI with system and case-level feedback. Training included a two-hour lecture, 30 minutes of video training, and one hour of simulation training. Audio recordings of suspected OHCAs from pre (P1, 10/5/10 - 11/6/11) and post-intervention (P2, 11/7/11 - 11/4/13) periods were collected by searching center archives for calls originally processed as cardiac arrests. Recordings were analyzed according to six key TCPR metrics. Times to telecommunicator recognition of cardiac arrest, start of TCPR instructions, and initiation of chest compressions were measured using a standardized timestamp format. Results: Rates of OHCA recognition (80% to 95%, p<0.0001), TCPR instructions started (32% to 72%, p<0.0001), and bystander chest compressions initiated (18% to 70%, p<0.001) all increased significantly. Reductions in the time from call receipt to the start of TCPR instructions (176s to 133s, p<0.0001) and to the start of compressions (265s to 162s, p<0.0001) were also observed. Conclusion: This bundled protocol, training and CQI intervention was associated with a significant increase in TCPR rates and a reduction in the time to first chest compression.
Abstract 11930: Sex Differences in Cardiac Troponin and the Risk of Death or Major Cardiovascular events in Men and Women With Diabetes and Coronary Artery Disease
Vlachos, Helen, Frye, Robert L. , Everett, Brendan M. , Brooks, Maria M. , Chaitman, Bernard , Bhatt, Deepak L.

Circulation | April 23, 2024 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.11930 Get It

Background: Circulating cardiac troponin T concentrations are higher in men than in women, but the biological causes and clinical implications of this observation are poorly understood. Methods and Results: We measured cardiac troponin T with a high-sensitivity assay (hsTnT) in 684 women and 1601 men with type 2 diabetes (T2D) and stable ischemic heart disease (SIHD) who were enrolled in the BARI 2D trial. Median (IQR) hsTnT was higher in men [12.4 ng/L (8.7-20.8)] than in women [9.1 ng/L (6.4-15.6); P<0.0001] and a higher proportion of men (43.6%) than women (29.1%) were above the current established upper reference limit of 14 ng/L (P<0.0001). Sex remained a significant predictor of natural log normalized hsTnT after adjusting for a wide array of covariables, including age, race, insulin use, renal function, ejection fraction, and HbA1c. Within quintiles of hsTnT measured at baseline, the 5-year incidence of the composite cardiovascular outcome of myocardial infarction, stroke, heart failure, or death was consistently higher in women than in men (Figure 1). In sex-stratified Cox models adjusting for possible confounders, the increase in the relative risk of the composite endpoint across quintiles of hsTnT appeared similar in men and women (Figure 2). Conclusions: In the BARI 2D trial, women have lower baseline hsTnT concentrations, but higher absolute risk of myocardial infarction, stroke, heart failure, or death for a given concentration of hsTnT. These data raise the question of whether sex-specific cutoffs for cardiac troponin T should be considered.
Abstract 11839: Hepatitis C sero-positivity Adversely Affects Long-term survival After Orthotropic Heart Transplant: Fifteen Year Analysis of a National Registry
Kumar, Sachin, Sarreyyupoglu, Basar, Elgudin, Yakov , Medalion, Benjamin, ElAmm, Chantal, Ginwalla, Mahazarin , Oliveira, Guilherme H., Park, Soon J., Kumar, Sachin, Deo, Salil V. , Altarabsheh, Salah E. , Dunlay, Shannon M. , Medalion, Benjamin, Fonarow, Gregg C.

Circulation | April 23, 2024 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.11839 Get It

Background: Concerns exist regarding orthotropic heart transplantation (OHT) in hepatitis C (HCV) seropositive recipients. The UNOS national registry was accessed to evaluate HCV recipient sero-positivity and outcomes. Method: Retrospective analysis of the UNOS registry (2000-2014) to evaluate recipient profile and clinical outcome of HCV sero-positive (HCV+ve) and sero-negative (HCV -ve) pts. Early and late adjusted survival and adverse events at follow-up were compared. Results: From 23,507 patients (mean age 52 yrs; 75% male), 481 (2%) were HCV +ve (mean age 52 yrs; 77% male). Annual proportion of HCV +ve recipients was comparable over the study period (range 1.3-2.7%; p=0.2). The HCV +ve cohort had more African American (22% vs 17%; p=0.01), pts with a prior LVAD (21 vs 14%; p<0.01 and more hepatitis B core Ag+ve recipients (17% vs 5%; p<0.01). However, ECMO (p=0.7), inotropic (p=0.2), and intra-aortic balloon pump (p=0.7) support, serum creatinine (p=0.7) and serum bilirubin (p=0.7) were similar. Proportion of Status 1A pts was similar (24% HCV+ vs 21% HCV -); however wait-time for HCV + recipients was longer (mean 23 vs 19 days; p<0.01). Among donor variables, age (p=0.8), hepatitis B status (p=0.4) and CDC high risk status (p=0.9) were comparable. At a median follow up of 4 years, 67.1% patients were alive, 28.4% died and 1.1% were re-transplanted (3.4% missing). Overall survival was worse in the HCV+ cohort (64.3 vs 72.9 % and 43.2 vs 55% at five and ten years; p<0.01). Late renal [OR 1.2(1-1.6); p = 0.02] and liver dysfunction [OR 4.5 (1.2-15.7); p=0.01] occur in HCV +ve recipients. On adjusted analysis, HCV sero-positivity is associated with poorer survival [HR0.6 (0.5-0.8); p<0.01]. Conclusion: A small proportion of patients receiving a heart transplant in the United States have hepatitis C. In spite of comparable pre-operative hepatic function, hepatitis C sero-positive recipients develop late liver dysfunction and have poorer long-term survival.